Drug · DIN 02529068
SITAGLIPTIN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 26, 2023; first marketed January 26, 2023.
- Drug Identification Number (DIN)
- 02529068
- Company (DIN owner)
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Sitagliptin A10BH01
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 5, 2023: NOC 29841Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Companies
Other DINs named SITAGLIPTIN
- DIN 02529033 · Marketed
- DIN 02529041 · Marketed
- DIN 02548550 · Marketed
- DIN 02548569 · Marketed
- DIN 02548577 · Marketed
- DIN 02545519 · Approved
- DIN 02545527 · Approved
- DIN 02545535 · Approved
- DIN 02558017 · Approved
- DIN 02558025 · Approved
- DIN 02558033 · Approved